EUVIMEDEUVIMED entdecken
Crossref

Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer

Yael Berner-Wygoda, Meredith Li, Chloe Perlon, Diego Malon, Neha Pathak, Massimo Di Iorio, Jacqueline Savill, Amal Aljuhani, Michelle B Nadler, Eitan Amir

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2025.04.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Yael Berner-Wygoda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, C…. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy. Die Arbeit nennt 12 Literaturangaben. Gefördert von: University Health Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyHumansFemalePaclitaxelCyclophosphamideTrastuzumabRetrospective StudiesMiddle AgedErb-b2 Receptor Tyrosine KinasesDoxorubicinAdultAgedNeoplasm StagingChemotherapy, AdjuvantOntario

Stichwörter der Autor:innen

Cost effectivnessDose denseHER2+ breast cancerNeoadjuvant therapyTime toxicity

Substanzen

PaclitaxelCyclophosphamideTrastuzumabErb-b2 Receptor Tyrosine KinasesDoxorubicinERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada. Electronic address: yael.berner-wygoda@uhn.ca.
  • Department of Medicine, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Ontario, Canada.
  • Department of Kinesiology and Physical activity, Faculty of education, McGill University, Quebec, Canada.
  • Gerald Bronfman Department of Oncology, St. Mary's Hospital Center, McGill University, Montréal, Quebec, Canada.

Förderung

  • University Health Network

Zitieren

APA

Berner-Wygoda, Y., Li, M., Perlon, C., Malon, D., Pathak, N., Di Iorio, M., Savill, J., Aljuhani, A., Nadler, M. B., & Amir, E. (2025). Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.04.017

Vancouver

Berner-Wygoda Y, Li M, Perlon C, Malon D, Pathak N, Di Iorio M, et al. Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.04.017

BibTeX
@article{BernerWygoda2025,
  author = {Berner-Wygoda, Yael and Li, Meredith and Perlon, Chloe and Malon, Diego and Pathak, Neha and Di Iorio, Massimo and Savill, Jacqueline and Aljuhani, Amal and Nadler, Michelle B and Amir, Eitan},
  title = {Safety and Effectiveness of Adriamycin and Cyclophosphamide Followed by Dose Dense (Every 2 Weeks) Paclitaxel Given With Trastuzumab as Neoadjuvant Treatment in HER2-Positive Early-Stage Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2025.04.017}
}
Kostenlos starten →